Erythropoietin-mediated Signaling in the Heart as a Potential Therapeutic Target in Chronic Heart Failure

2007 ◽  
Vol 13 (6) ◽  
pp. S22-S23
Author(s):  
Yutaka Kagaya ◽  
Yasuhide Asaumi ◽  
Tomohiro Tada ◽  
Nobuyuki Shiba ◽  
Kunio Shirato ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure

2011 ◽  
Vol 15 (11) ◽  
pp. 2443-2451 ◽  
Author(s):  
Shiang Y. Lim ◽  
Derek J. Hausenloy ◽  
Sapna Arjun ◽  
Anthony N. Price ◽  
Sean M. Davidson ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Therapeutic Target ◽  
Post Myocardial Infarction ◽  
Cyclophilin D ◽  
Potential Therapeutic Target ◽  
Infarction Heart

Ventricular-arterial coupling as a potential therapeutic target in diabetes

2021 ◽  
Author(s):  
Sahrai Saeed ◽  
Hannes Holm ◽  
Peter Nilsson
Keyword(s):  
Heart Failure ◽  
Therapeutic Target ◽  
Cardiovascular Complications ◽  
Left Ventricular ◽  
Arterial System ◽  
Protective Effects ◽  
Potential Therapeutic Target ◽  
Lower Plasma Glucose ◽  
Glucagon Like Peptide 1 ◽  
Long Term Prognosis

Patients with type 2 diabetes (T2D) are at high risk of cardiovascular complications. Novel anti-diabetic medications such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to possess cardiac and renal protective effects beyond their ability to lower plasma glucose. Use of SGLT-2i and GLP-1RA in patients with T2D and heart failure reduce cardiovascular risk and heart failure related hospitalizations. SGLT-2i treatment has shown to improve the long-term prognosis of patients with heart failure. Both drugs also have the potential to normalize ventricular-arterial coupling (VAC). VAC is the crosstalk between the left ventricular function and the arterial system, and is an indicator of the global cardiovascular performance. In this overview, we will describe the concept of VAC and the features of diabetic cardiomyopathy, as well as VAC as a potential therapeutic target in diabetes by use of novel anti-diabetic drugs, primarily SGLT-2i and GLP-1RA. Continuous...

Hyponatremia in acute heart failure syndromes: A potential therapeutic target

2007 ◽  
Vol 4 (4) ◽  
pp. 207-213 ◽  
Author(s):  
Filippo Brandimarte ◽  
Francesco Fedele ◽  
Leonardo De Luca ◽  
Gregg C. Fonarow ◽  
Mihai Gheorghiade
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Acute Heart Failure Syndromes

Soluble guanylate cyclase: a potential therapeutic target for heart failure

2012 ◽  
Vol 18 (2) ◽  
pp. 123-134 ◽  
Author(s):  
Mihai Gheorghiade ◽  
Catherine N. Marti ◽  
Hani N. Sabbah ◽  
Lothar Roessig ◽  
Stephen J. Greene ◽  
...  
Keyword(s):  
Heart Failure ◽  
Guanylate Cyclase ◽  
Therapeutic Target ◽  
Soluble Guanylate Cyclase ◽  
Potential Therapeutic Target

scholarly journals Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

2013 ◽  
Vol 16 (1) ◽  
pp. 76-85 ◽  
Author(s):  
Daniela Dobre ◽  
Jeffrey S. Borer ◽  
Kim Fox ◽  
Karl Swedberg ◽  
Kirkwood F. Adams ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Prognostic Factor ◽  
Therapeutic Target
Sign in / Sign up

Export Citation Format

Share Document